Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
2.

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism.

Abu Assab T, Raveh-Brawer D, Abramowitz J, Naamad M, Ganzel C.

Acta Haematol. 2019 Sep 11:1-6. doi: 10.1159/000502348. [Epub ahead of print]

PMID:
31509839
3.

Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).

Duek A, Trakhtenbrot L, Amariglio N, Benyamini N, Zilbershats I, Ganzel C, Shevetz O, Leiba R, Rozic G, Nagler A, Leiba M.

Genes Chromosomes Cancer. 2019 Aug;58(8):516-520. doi: 10.1002/gcc.22738. Epub 2019 Feb 6.

PMID:
30675954
4.

The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study.

Ganzel C, Silverman B, Chemtob D, Ben Shoham A, Wiener-Well Y.

Leuk Lymphoma. 2019 Mar;60(3):720-725. doi: 10.1080/10428194.2018.1499904. Epub 2018 Sep 6.

PMID:
30188229
5.

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.

Ganzel C, Kharit M, Duksin C, Rowe JM.

Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28. No abstract available.

6.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

7.

Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.

Cohen YC, Saranga A, Gatt ME, Lavi N, Ganzel C, Magen H, Avivi I, Tadmor T, Suriu C, Jarchowsky Dolberg O, Papushado A, Trestman S, Ram R.

Am J Hematol. 2018 Jun;93(6):810-815. doi: 10.1002/ajh.25098. Epub 2018 Apr 28.

8.

Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.

Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group.

Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2.

PMID:
29501828
9.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

10.

Revisiting autologous transplantation in acute myeloid leukemia.

Ganzel C, Rowe JM.

Curr Opin Hematol. 2018 Mar;25(2):95-102. doi: 10.1097/MOH.0000000000000408. Review.

PMID:
29324476
11.

Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Bentur OS, Gurion R, Gafter-Gvili A, Gatt M, Shvidel L, Horowitz NA, Ram R, Herishanu Y, Sarid N, Paltiel O, Ganzel C, Kreiniz N, Dally N, Gutwein O, Raanani P, Avivi I, Perry C.

Leuk Lymphoma. 2018 May;59(5):1163-1171. doi: 10.1080/10428194.2017.1375102. Epub 2017 Sep 13.

PMID:
28901817
12.

Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.

Ganzel C, Reinus C.

Blood. 2017 Jan 12;129(2):268. doi: 10.1182/blood-2016-08-732784. No abstract available.

PMID:
28082296
13.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

14.

Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.

Shaulov A, Ganzel C, Benyamini N, Barshay Y, Goldschmidt N, Lavie D, Libster D, Gural A, Avni B, Gatt ME.

Am J Hematol. 2017 Feb;92(2):131-135. doi: 10.1002/ajh.24596. Epub 2016 Nov 21.

15.

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS.

J Clin Oncol. 2016 Oct 10;34(29):3544-3553. Erratum in: J Clin Oncol. 2017 Jan 10;35(2):263.

16.

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?

Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, Hardan I, Zilbershats I, Ganzel C, Shevetz O, Novikov I, Cohen Y, Ishoev G, Rozic G, Nagler A, Trakhtenbrot L.

Genes Chromosomes Cancer. 2016 Sep;55(9):710-8. doi: 10.1002/gcc.22372. Epub 2016 Jun 24.

PMID:
27152944
17.

Autologous transplant remains the preferred therapy for relapsed APL in CR2.

Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, Wang H, Zhang MJ, Weisdorf D, Douer D, Rowe JM, Polge E, Esteve J, Nagler A, Mohty M, Tallman MS.

Bone Marrow Transplant. 2016 Sep;51(9):1180-3. doi: 10.1038/bmt.2016.96. Epub 2016 Apr 18.

18.

Pneumococcal infection is associated with relatively marked peripheral blood leukocytosis.

Manor J, Wiener-Well Y, Ganzel C.

J Infect. 2016 Jun;72(6):756-759. doi: 10.1016/j.jinf.2016.03.007. Epub 2016 Mar 19. No abstract available.

PMID:
27000645
19.

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.

Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H.

Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16.

PMID:
26567759
20.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O.

Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13.

21.

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM.

Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17.

22.

Parvovirus B19 diagnosed by bone marrow biopsy.

Ganzel C, Constantin R.

Blood. 2015 May 21;125(21):3351. No abstract available.

PMID:
26199969
23.

Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy.

Ganzel C, Devlin S, Douer D, Rowe JM, Stein EM, Tallman MS.

Br J Haematol. 2015 Jul;170(1):50-5. doi: 10.1111/bjh.13386. Epub 2015 Mar 30.

PMID:
25823602
24.

Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.

Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C.

Am J Hematol. 2015 Jul;90(7):675-8. doi: 10.1002/ajh.23971. Epub 2015 Feb 27. No abstract available.

25.

Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.

Mazor RD, Manevich-Mazor M, Kesler A, Aizenstein O, Eshed I, Jaffe R, Pessach Y, Goldberg I, Sprecher E, Yaish I, Gural A, Ganzel C, Shoenfeld Y.

BMC Med. 2014 Dec 1;12:221. doi: 10.1186/s12916-014-0221-3.

26.

Rapid oral allopurinol desensitization in a patient with chronic myeloid leukemia.

Toker O, Tvito A, Rowe JM, Ashkenazi J, Ganzel C, Tal Y, Shalit M.

Isr Med Assoc J. 2014 Jul;16(7):461-2. No abstract available.

27.

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2014 Nov 6;124(19):3016-9. doi: 10.1182/blood-2014-04-570937. Epub 2014 Aug 22.

28.

Extramedullary disease in APL: a real phenomenon to contend with or not?

Ganzel C, Douer D.

Best Pract Res Clin Haematol. 2014 Mar;27(1):63-8. doi: 10.1016/j.beha.2014.04.001. Epub 2014 Apr 12. Review.

PMID:
24907018
29.
30.

Pegfilgrastim prophylaxis for cladribine-induced neutropenia in patients with hairy-cell leukemia.

Goldschmidt N, Ganzel C, Attias D, Gatt M, Polliack A, Tadmor T.

Acta Haematol. 2014;132(1):118-21. doi: 10.1159/000358293. Epub 2014 Feb 14. No abstract available.

PMID:
24557414
31.

Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.

Ganzel C, Douer D, Tallman MS.

J Natl Compr Canc Netw. 2013 Dec 1;11(12):1512-21. Review.

PMID:
24335686
32.

How I treat hematologic emergencies in adults with acute leukemia.

Zuckerman T, Ganzel C, Tallman MS, Rowe JM.

Blood. 2012 Sep 6;120(10):1993-2002. doi: 10.1182/blood-2012-04-424440. Epub 2012 Jun 13.

PMID:
22700723
33.

Total ambulatory hemato-oncological care: a myth or reality?

Ganzel C, Rowe JM.

Leuk Lymphoma. 2012 Dec;53(12):2335-6. doi: 10.3109/10428194.2012.700516. Epub 2012 Jul 9. No abstract available.

PMID:
22680775
34.

Separate diagnoses of Hodgkin lymphoma and non-Hodgkin lymphoma in an individual patient might not signify a common clonal origin.

Ganzel C, Pogrebijsky G, Krichevsky S, Neuman T, Yehuda DB.

Exp Hematol. 2012 Sep;40(9):698-704.e2. doi: 10.1016/j.exphem.2012.05.009. Epub 2012 Jun 1.

PMID:
22659385
35.

Hyperleukocytosis, leukostasis and leukapheresis: practice management.

Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM.

Blood Rev. 2012 May;26(3):117-22. doi: 10.1016/j.blre.2012.01.003. Epub 2012 Feb 23. Review.

PMID:
22364832
36.

Prognostic factors in adult acute leukemia.

Ganzel C, Rowe JM.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1163-87. doi: 10.1016/j.hoc.2011.09.017. Review.

PMID:
22093582
37.

High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.

Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N.

Leuk Lymphoma. 2012 Jun;53(6):1169-73. doi: 10.3109/10428194.2011.635864. Epub 2011 Dec 7.

PMID:
22035415
38.

Primary effusion lymphoma in a HIV-negative patient associated with hypogammaglobulinemia.

Ganzel C, Rowe JM, Ruchlemer R.

Am J Hematol. 2011 Sep;86(9):777-81. doi: 10.1002/ajh.22068. Epub 2011 May 31. No abstract available.

Supplemental Content

Loading ...
Support Center